HCP Live June 22, 2024
Patrick Campbell

Details of an analysis from ADA 2024 compared matched cohorts from SURMOUNT-1 and SURMOUNT-2 to determine drivers of differences in weight loss from the trials.

An analysis of the SURMOUNT 1 and 2 trials presented at the 84th American Diabetes Association Scientific Sessions offers further insight into the differences in weight loss observed among people with and without type 2 diabetes achieved with use of tirzepatide.

Results of the study, which leveraged propensity score matching and mixed models for repeated measures (MMRM) analysis to compare the effect of Eli Lilly and Company’s dual GIP/GLP-1 receptor agonist in those with overweight or obesity based on diabetes status, suggest the differences in weight reductions observed persisted after matching key baseline characteristics, which...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Clinical Trials, Conferences / Podcast, Patient / Consumer, Pharma / Biotech, Provider, Trends
Seattle biotech startup Bonum upgrades offices, expands team in its pursuit of cancer drugs
Pfizer, Valneva inch closer to FDA approval of 1st Lyme disease vaccine
New Gene Therapy for Muscular Dystrophy May Facilitate Development of Others
Weight Loss Drugs’ Effects Could Be Improved by Priming Melanocortin System
J&J IRA pricing offer is in, as it sticks with 2025 guidance

Share This Article